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1. INTRODUCTION 1 
 2 
1.1 Hepatocellular adenoma 3 
Hepatocellular adenomas (HCA) are benign tumors caused by proliferation of 4 
hepatocytes with a high content of glycogen and fat. They constitute 2% of all 5 
liver tumors and their most important complications are hemorrhage and 6 
malignant transformation to hepatocellular carcinoma (HCC) (1). 7 
HCA are characterized by a tumor parenchyma with numerous arteries, 8 
unaccompanied by bile ducts and a cytoplasm that may be either normal, 9 
glycogenotic or steatotic. They show sinusoidal dilatation, infarcts, and 10 
haemorrhage, and may result in oedematous or fibrotic regions. Haemorrhage is 11 
more frequent in HCA with sinusoidal dilatation and congestion (2), and can 12 
usually occur in HCA bigger than 4–5 cm. Haemorrage can be either inside the 13 
nodule, usually admixed with necrotic changes, or spontaneous haemorrhagic 14 
rupture which can cause subcapsular haematoma and haemoperitoneum. The 15 
diagnosis of HCA is usually made on routine HE staining, while 16 
immunohistochemistry is necessary for the classification into the different 17 
subtypes (3), that is important for the follow-up and management of the patient 18 
(4). In fact, HCA are monoclonal tumors characterized by several recurrent 19 
mutations (5-8) and are subclassified into 4 groups, according to their genotype 20 
and phenotype (5). 21 
- HHCA, characterized by inactvating mutation of HNF1A gene. 22 
HNF1A gene encodes the Hepatocyte Nuclear Factor 1 α (HNF1α). a tumor 23 
suppressor gene involved in liver tumorigenesis (6).  24 
HHCA account for the 35–40% of HCA and mostly correspond to a 25 
histologically homogeneous group of tumors, characterized by marked 26 
steatosis, no cytological abnormalities, no inflammatory infiltrates. 27 
Furthermore, FABP1 (liver fatty acid binding protein), which is a gene 28 
positively regulated by HNF1A, and expressed in normal liver tissue, 29 
displays downregulated expression levels in HHCA. In fact, in 30 
immunohistochemistry, LFABP (liver fatty acid binding protein) is negative 31 
in the tumor while it shows a normal expression in the surrounding non-32 
tumoral tissue (3). Tumor borders are well delineated because of the 33 
 5 
differences in  LFABP expression and presence of steatosis between tumor 1 
and adjacent normal liver. HHCA often show adenomatosis, as multiple 2 
adenomas of varying size, associated with a several steatotic micronodules. 3 
 4 
-  bHCA, characterized by activating mutations of the β-Catenin gene: 5 
β-Catenin mutations activate the Wnt/β-catenin pathway that is involved in 6 
lineage specification, differentiation, stem cell renewal, proliferation, cell 7 
adhesion and liver regeneration. bHCA are at greater risk of malignant 8 
transformation, and mutations of β-catenin are also found in 20–30% of 9 
hepatocellular carcinomas. bHCA account for the 10–15% of HCA, and the 10 
usual anti-bcatenin immunohistochemical pattern results in an aberrant 11 
nuclear and cytoplasmic posititvity, distributed in a random and 12 
heterogenous pattern. Furthermore, Glul, a β-catenin target gene, coding for 13 
glutamine synthetase, also displays upregulated expression. Therefore, these 14 
bHCA show also strong and diffuse glutamine synthetase staining (3). 15 
bHCA are often extremely difficult to distinguish from well-differentiated 16 
HCC, due to the cytological and architectural abnormalities. Moreover, they 17 
are also more frequently associated with the malignant transformation to 18 
HCC than other HCA subtypes (2-5). This subgroup of bHCA is 19 
overrepresented in male patients and specific risk factors are often found, 20 
such as male hormone administration, glycogenosis, and familial polyposis. 21 
However, death due to HCC was more often linked to women with this type 22 
of β-HCA in our own series (4). 23 
 24 
- IHCA Inflammatory Hepatocellular Adenomas:  25 
IHCA account for more than 50% of all HCA, and  are characterized by the 26 
presence of inflammatory infiltrates, sinusoidal dilatation, thick-walled 27 
arteries, and ductular reaction. They show overexpression of molecules of 28 
the acute-phase inflammatory response, such as serum amyloid A (SAA) 29 
and C-reactive protein (CRP) (3), confirmed by immunohistochemical 30 
analysis.   31 
Steatosis may be present and is usually distributed irregularly within the 32 
IHCA. Approximately 10% of IHCA have a mutation in the β-catenin gene. 33 
 6 
The risk of HCC does also exist in these inflammatory/β-HCA, but in a 1 
proportion that is presently unknown.  2 
Some HCA are associated with gain-of-function mutations caused by in-3 
frame somatic deletions in the IL6ST gene (8). This gene encodes for the 4 
signalling co-receptor gp130. Mutant gp130 constitutively activates STAT3 5 
signalling in the absence of IL-6 binding. gp130 and β-catenin mutations 6 
may coexist in a same HCA.  7 
 8 
- UHCA, unclassified hepatocellular adenomas 9 
Tumors in this group represent less than 5–10% of cases, and they do not 10 
show HNF1A or β-catenin gene mutations and do not express inflammatory 11 
proteins.  12 
 13 
1.2 HCC 14 
    There is a small but definite incidence of malignant transformation of HCA (2-15 
5). This could be demonstrated by the co-existence of both HCA and HCC within 16 
the same tumor and the occurrence of an overt HCC several years after partial 17 
resection of a HCA. However, the exact pathways of malignant transformation 18 
and the exact point at which the switch to malignant transformation occurs remain 19 
unknown. The risk of malignancy is particularly higher for bHCA, which are most 20 
frequently associated with glycogenosis type 1, androgenic hormone intake, and 21 
familial adenomatous polyposis. Since bHCA often show cytological atypia and 22 
pseudoglandular pattern, it is often very difficult and sometimes almost 23 
impossible to differentiate these from a well-differentiated HCC. Although 24 
glypican-3 is a promising marker for the identification of HCC, its utility is limited 25 
by the fact that it may not be detected in approximately one third of HCC which 26 
develop in a normal liver. In inflammatory HCA, we suspect that β-catenin 27 
mutation is a secondary event that occurs at a late time. 28 
HCA occurs in women with a history of oral contraception and in other conditions 29 
such as Fanconi’s anemia and metabolic syndrome [9]. It has been reported that 30 
malignancy within HCA in women with a history of oral contraception is rather 31 
 7 
low (< 4%), while the risk of malignant transformation in men is 10 times more 1 
frequent and is mostly associated with metabolic syndrome (10). HCA is also 2 
often are associated with Glycogen Storage Disease (GSD), especially type I and 3 
III. 4 
 5 
1.3 Glycogen Storage Disease 6 
GSD1a is an autosomal recessive metabolic disorder that occurs approximately 7 
once in every 100,000 live births (11). GSD1a is caused by a mutation in the 8 
catalytic subunit of glucose-6-phosphatase-a (G6Pase-a) (12), a key enzyme in 9 
glucose homeostasis. G6Pase-a is expressed primarily in liver, kidney and 10 
intestine, and catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose 11 
and phosphate (13), the terminal steps in gluconeogenesis and glycogenolysis 12 
(Fig. 1).  13 
 14 
 15 
                                                                                                             From Chou JY, The Molecular Basis of Type 1 Glycogen Storage Diseases, 2001 16 
 8 
Figure 1. The primary anabolic and catabolic pathways of G6Pase in gluconeogenic 1 
organs. G6Pase-a is shown embedded within the membrane of the endoplasmic reticulum. 2 
GLUT2, the transporter responsible for the transport of glucose in and out of the cell in liver, 3 
kidney and intestine, is shown embedded in the plasma membrane. Abbreviations: G6P, 4 
glucose-6-phosphate; G6Pase-a, glucose-6-phosphatase-a; G6PT, glucose-6-phosphate 5 
transporter; GLUT2, glucose transporter 2, P, phosphate; P’ inorganic phosphate; UDP 6 
uridine diphosphate. 7 
 8 
 9 
GSD1a patients are unable to maintain glucose homeostasis and show growth 10 
retardation, hypoglycemia, hepatomegaly, kidney enlargement, hyperlipidemia, 11 
hyperuricemia, and lactic acidemia. Long-term symptoms include gout, 12 
osteoporosis, renal failure, and  hepatic adenomas with risk for malignancy. The 13 
disease is controlled by dietary therapies, which consist of continuous nasogastric 14 
infusion of glucose (14) or frequent oral administration of uncooked cornstarch 15 
(15), to prevent hypoglycemia. 16 
Unfortunately, the control of hypoglycemia cannot prevent the progressive 17 
deterioration of liver and kidney. Liver dysmetabolism is severe, hepatocytes 18 
become enlarged and loaded with glycogen and triglycerides containing vesicles, 19 
and the hematochemical parameters are altered with high triglycerides and 20 
cholesterol content. Persistency of liver dysmetabolism during patient’s ageing 21 
results in a progressive worsening of the clinical parameters, like the formation of 22 
hepatocellular adenomas (HCA), which are likely to be multifocal, and progress 23 
to liver carcinoma (HCC) in 10% of the cases (16-18). 52% of GSD adenomas 24 
can be classified as IHCA, 28% as bHCA, and the remaining 20% as UHCA (19). 25 
The elevated percentage of adenomas with b-catenin activating mutations may 26 
explain the risk of malignant transformation of HCA in HCC in GSD1a patients.  27 
Liver transplant is the only option in the most severe cases. GSD1a patients exhibit 28 
marked variability in the severity of symptoms and complications and the 29 
underlying pathological pathways that develop with the progress of the disease 30 
are poorly understood. The underlying pathological pathways that develop with 31 
age are poorly understood, and there are no biomarkers associated with the 32 
variability of the progressive tissue alterations (20), no indication of causes of the 33 
 9 
worsening of the clinical situation and no treatment protocol to deal with the 1 
HCA/HCC.  2 
 3 
1.4 Animal Models 4 
There are two main mouse models for GSD-1a, closely mimicking the human 5 
disorders. The first model, developed by Dr. Chou is a KO mouse (G6pc-/-) (21). 6 
These animals are very fragile, they die within three weeks after birth, if untreated, 7 
and, therefore, they are unsuitable for studying long-term complications of 8 
GSD1a. So, to provide insights into the progressive age-dependent liver 9 
degeneration in GSD-1a, we have developed in 2014 a new and clinically relevant 10 
murine model, LS-G6pc-/-, conditional for the liver, that displays variability in the 11 
severity of the complications and the long-term consequences of the hepatic 12 
degeneration, similar to what is observed in GSD-1a patients (22). 13 
 14 
1.5 LS-G6pc-/- mice 15 
LS-G6pc-/- mice manifest a milder pathological situation in comparison with 16 
G6pc-/- mice. Nevertheless, LS-G6pc-/- mice exhibit hepatic symptoms similar 17 
to those of the human GSD-1a and, therefore, represent a valid model to 18 
evaluate long-term complication and HCA progression (22).  19 
 20 
Histology and histochemistry 21 
LS-G6pc-/- mice are viable and fertile and show no growth retardation. On the 22 
other hand, LS-G6pc-/- mice manifest a liver phenotype typical of GSD-1a, 23 
characterized by hepatomegaly. This clinical presentation in GSD-1a is primarily 24 
caused by excess of glycogen and lipid deposition. LS-G6pc-/- mic show marked 25 
glycogen deposit in the hepatocytes, compared with WT mice (Fig. 2A, B). 26 
Steatosis in LS-G6pc-/- mice is revealed by the presence of macro- and micro-lipid 27 
vesicles in the enlarged hepatocytes (Fig. 2A, arrows). Activity of G6Pase is 28 
detectable in the livers of wild type mice (Fig. 2D), in contrast to the livers of LS-29 
G6pc-/- mice for which staining is negative (Fig. 2C).  30 
The glycogen content in the livers of LS-G6pc-/- mice is significantly higher than 31 
that of control, increasing with mice ageing to reach 60mg/g of liver in 10-15 32 
 10 
month old mice (Fig. 2E, F). Similarly, accumulation of triglycerides in LS-G6pc-1 
/- livers significantly increases with age, in agreement with the marked Oil red O 2 
staining of liver sections (Fig. 2G, H) (22). 3 
 4 
 5 
Figure 2. Histological and histochemical analysis of livers from LS-G6pc-/- and control 6 
mice. Paraffin-embedded, H&E-stained liver sections from a 2 month old LS-G6pc-/- mouse 7 
(A)  and control mouse (B). To evaluate the G6Pase activity, liver cryostat sections were 8 
treated as described in Material and Methods. Colored lead sulfide was developed with 9 
ammonium sulfide. Representative results of liver sections from 3 month old LS-G6pc-/- (C) 10 
and control (D) mice are shown. Paraffin-embedded liver sections from a 3 month old LS-11 
G6pc-/- mice were stained with PAS (E) or PAS plus diastase (F). Oil red O staining of LS-12 
 11 
G6pc-/- mouse (A) or control mouse (B) liver cryostat sections at 2 months of age shows lipid 1 
accumulation in the hepatocytes of LS-G6pc-/- mouse.  (A, B, E and F) 10X magnification, 2 
(C, D, G and H) 20X magnification. 3 
 4 
 5 
Metabolic characteristics of LS-G6pc-/- mice. 6 
Glu-6- P phosphohydrolase activity in the liver of LS-G6pc-/- is undetectable (Fig. 7 
3A).  8 
LS-G6pc-/- mice suffer from fasting hypoglycemia typical of GSD-1a. The mean 9 
serum glucose level in LS-G6pc-/- mice is significantly lower than that in control 10 
littermates after 6 hours fasting (Fig. 3B). These mice, though, do not suffer from 11 
hypoglycemic seizure and therefore do not require glucose therapy, like the G6pc-12 
/- mice (21). In fact, in the fed state, the mean blood glucose concentration in LS-13 
G6pc-/- mice is 25% lower than in control mice, but remained within the normal 14 
levels. Moreover, serum cholesterol and triglycerides mean levels are higher in 15 
LS-G6pc-/- mice 2-4 months old than in control littermates (Fig. 3C,D), but they 16 
show  improvement of serum cholesterol and triglycerides levels in mice older 17 
that 6 months (Fig. 3C,D) (22).   18 
Finally, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 19 
are moderately to mildly increased in LS-G6pc-/- mice as compared to healthy 20 
controls (data not shown). 21 
 22 
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Figure 3. Hepatic G6Pase activity, plasma glucose, cholesterol and triglyceride levels in 1 
LS-G6pc-/- mice. Metabolic functions were analyzed in LS-G6pc-/- mice. 3 to 5 mice were 2 
analyzed for each group. G6Pase activity (A), blood glucose (B), triglycerides (C), and total 3 
cholesterol (D) were analyzed at the indicated ages in weeks (w) or months (m). Because of 4 
the similarities of the respective metabolites in each group of control mice, results shown are 5 
pooled data of age 2 weeks-20 months. 4 control mice were analyzed for each group. (A’) 6 
Western blot analysis of liver tissues for G6Pase-a expression. (B) Glucose levels was 7 
determined in the fed state (dark grey bars) or upon 6 hrs fasting (light grey bars). Data are 8 
presented as mean ± SD. Values which are significantly different from control mice (P 9 
<0.05*, P <0.01** and ***P < 0.005) are indicated. 10 
 11 
 12 
Progressive liver damage with age. 13 
The severity of liver damage increases as mice grew older. By two months of age 14 
areas of paucicellular necrosis with inflammatory cells start to appear (Fig. 4A,B), 15 
and initial damage of liver structure could be observed by sinusoid and vein 16 
enlargement (Fig. 4C) (22). 17 
In livers of older mice (aged 6 to 20 months) portal and periportal inflammatory 18 
infiltrates are detected (Fig. 4D). Moreover, marked amyloid deposition is 19 
observed in 90% of the livers of mice older than 10 months of age (Fig. 4E,F). 20 
Deposits is observed both in vessel walls and within sinusoids. The material is 21 
positive to Congo Red (Fig. 4F) and displays green birefringence when viewed 22 
under polarized light (data not shown), confirming amyloid deposition.  23 
Thus, even if the metabolic parameters tend to normalize as the mice age, hepatic 24 
degeneration worsens and the progressive degeneration of the liver leads to 25 
premalignant and malignant transformation. By 10 months of age, 40% of LS-26 
G6pc-/- mice develop HCA and HCC (Fig. 5A,B). Therefore, LS-G6pc-/- mice 27 
manifest most of the liver damages of GSD1a and develop hepatic long term-28 
complications such as those affecting GSD1a patients (22).  29 
Finally, LS-G6pc-/- mice develop marked vascular and sinusoidal amyloidosis. To 30 
our knowledge, amyloidosis has been reported only once in GSD1b patients (23)  31 
and never in GSD-1a patients or in the other GSD-1a animal models. However, 32 
the presence of amyloidosis in the livers of LS-G6pc-/- mice remains and further 33 
studies will be necessary to determine the reasons for the occurrence of this 34 





Figure 4. Histological appearance of liver in adult mouse. (A) H&E and (B) reticulin 4 
staining shows foci of necrosis in a 2 month old  LS-G6pc-/- mouse. (C) Liver section of a 4 5 
month old LS-G6pc-/-  mouse showing sinusoid and vein enlargement. (D) Liver section of a 6 
8 month old LS-G6pc-/- mouse with inflammatory infiltrates. (E) Liver section of a 15 month 7 
old LS-G6pc-/- mouse with inflammatory infiltrates (arrowheads) and sinusoidal amyloidosis 8 
(arrows) stained with H&E. (F) Extended  amyloidosis is confirmed by Congo Red staining. 9 


















 Figure 5. Liver nodules in ageing LS-G6pc-/- mice. (A) Liver resection of a 19 month old 13 
L-G6pc-/- mouse with a 10 mm nodule (arrow). Smaller nodules are also present (arrowhead). 14 
(B) H&E stained section from the liver of a 12 month old LS-G6pc-/- mouse showing a nodule 15 






2. AIM OF THE STUDY 1 
The aim of this project has been to study liver degeneration and HCA and HCC 2 
development in the conditional mouse model of GSD1a, by using three different 3 
approaches: 4 
 5 
2.1. MRI analysis of LS-G6pc-/- mice to identify and classify liver lesions. 6 
Magnetic Resonance Imaging (MRI) represents an important tool to differentiate 7 
benign and malignant hepatic lesions especially because of the possibility to 8 
combine information obtained with different sequences, such as T1 and T2 9 
weighted imaging (WI), diffusion WI (DWI) and post contrast T1WI using 10 
hepatobiliary gadolinium contrast agents, such as  gadobenate dimeglumine (Gd-11 
BOPTA) and gadoxetic acid (Gd-EOB) (24). 12 
Correlation between MRI and the genotype-phenotype classification of HCA has 13 
been attempted (25-27). Characteristic MRI profiles for HHCA and IHCA have 14 
been identified while no specific MRI profile can be proposed for the 15 
identification of high-risk bHCA cases. In consideration of this, the subtyping and 16 
classification of liver adenomas for HCC risk prediction in humans still requires 17 
invasive procedures, i.e. biopsies.  18 
A preclinical experimental approach may help to develop a method to better 19 
identify MRI features specifically associated with bHCA subtype. In this study 20 
we assessed the detection level and quantified the longitudinal evolution of liver 21 
lesions in LS-G6pc-/- mice in order to characterize HCA and HCC using a 22 
dedicated protocol, optimized for high magnetic field strength, and a hepato-23 
specific contrast agent.  24 
We show here that bHCA display MRI features distinguishable from those 25 
exhibited by IHCA or UHCA, indicating that MRI is a reliable method to identify 26 
high-risk HCA. 27 
 28 
2.2 Proteomic analysis on liver specimens from LS-G6pc-/- mice. 29 
Although transcriptional profiling provides an in-depth understanding of gene-30 
expression changes in disease, limited agreement between transcriptional changes 31 
and protein level changes has been observed across various studies and in different 32 
cell types (28,29). Proteomic studies should provide an important perspective for 33 
 16 
understanding pathophysiological changes that result in liver pathology (30).  The 1 
simultaneous characterization of cell abundance of hundreds of proteins should 2 
make it possible to identify significant global protein expression changes in 3 
response to different biological conditions. To date, many studies have focused 4 
on characterizing diseased vs. normal liver proteomes (31,32). We determined the 5 
proteomic expression changes in the liver of LS-G6pc-/- mice in comparison with 6 
wild type mice to identify potential biomarkers of the pathophysiology of the 7 
affected liver. We show that LS-G6pc-/- livers display an age-dependent 8 
modulation of the expression of proteins belonging to specific biological 9 
processes associated with the progression of liver disease. Moreover, proteins that 10 
are hallmarks of hypoxia were persistently upregulated in the liver of these mice, 11 
while the acute inflammatory and immune response were among the significantly 12 
enriched biological processes in LS-G6pc-/- mice with adenomas in comparison 13 
with mice without tumors. Finally, different proteins involved in the process of 14 
tissue inflammation and macrophage polarization toward the M2 phenotype were 15 
upregulated.  Our results are compatible with a metabolic reprogramming of 16 
glucose-6-P leading to enhanced glycolysis, lactate production, increased 17 
lipogenesis and cholesterol synthesis, and dysfunction in oxidative 18 
phosphorylation. Moreover, our results identify in the liver a pathologic 19 
environment, represented by hypoxia, inflammation, and macrophage M2 20 
polarization, that may lead to tumor development and progression.  21 
 22 
2.3 Identification of liver selective exosomal miRNA signatures on blood 23 
The existence of a communication network between pathologic tissues and their 24 
environment through shedding of exosomes, membrane microvesicles 25 
transporting cellular contents, has been shown in several diseases including cancer 26 
(33-37). In vitro studies have revealed that exosomes can play an important role 27 
in the development and progression of cancer through modulation of intercellular 28 
communication within the tumor microenvironment by the transfer of protein, 29 
lipid, and RNA cargo. For example, breast cancer microvesicles stimulate 30 
angiogenesis and platelet-derived microvesicles promote tumor progression and 31 
metastasis of lung cancer cells (38,39). The exosomes have received a great deal 32 
of attention also for their biomarker potential. The utilization of blood exosomes 33 
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as surrogate tissue to diagnose, monitor, and predict disease evolution and 1 
response to therapy would be a poorly invasive, highly desirable alternative to 2 
biopsies. Furthermore, the use of exosomes seems to be an indispensable approach 3 
to deal with situations in which the pathological tissue is not readily available for 4 
analysis.  5 
Exosomes may provide an excellent biomarker to monitor the emergence, 6 
progression, and prognosis of cancer, as well as the efficacy of treatment regimes. 7 
Studies have revealed that exosomes can be readily detected in many body fluids, 8 
and can be found in higher concentrations in the serum and plasma of cancer 9 
patients. The fact that exosomes often reflect the disease state and can be easily 10 
detected in bodily fluids makes them an ideal candidate for a non-invasive 11 
biomarker of tumor progression. Several reports identified potential exosomal 12 
biomarkers in patients' specimens (40). MicroRNA (miRNA) are exosome 13 
constituents actively studied as biomarkers for their stability, as 14 
diagnostic/prognostic indicators for their mirroring cellular components and as 15 
source of indication of therapeutic targets for their biological activities. miRNA 16 
are small cellular RNA inhibiting gene expression and often form a tissue 17 
selective pattern. Aberrant miRNA expression profiles were reported in cancer, 18 
rare diseases, and tissue degeneration (41). Therefore, the analysis of blood 19 
exosomes is a choice approach to study pediatric diseases because of the 20 
difficulties in obtaining tissue specimens. Our animal model, in which only the 21 
liver is affected, is ideal to identify exosomal miRNA contribution the specific 22 
pathologic manifestations of liver. This approach focuses on exosomal miRNA 23 
(exo-miR) evaluation in the blood of LS-G6pc-/- mice GSD1a patients to derive 24 
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      3. MATERIALS AND METHODS 1 
 2 
3.1 Housing and breeding of mice 3 
All animals were maintained in a conventional animal facility in 12-h light/dark 4 
cycles, fed at libitum, and monitored for their lifespan. All animal studies were 5 
reviewed and approved by the Ethical Committee for Animal Experimentation 6 
(CSEA) as Animal Use project n. 291 communicated to the Italian Ministry of 7 
Health having regard to the article of the D.lgs 116/92, and carried out at the 8 
animal facility of the National Institute for Cancer Research (Genova, Italy). 9 
 10 
3.2. MRI analysis in mice  11 
MRI was performed with a clinical 3T MR system (Signa EXCITE®HDxT, GE, 12 
Milwaukee, USA). Qualitative and quantitative analysis were performed on a 13 
commercially available workstation (AW Volume Share 2, ADW 4.4, GE, Milan, 14 
Italy). 15 
Mice were anesthetized by intraperitoneal injection of xylazine (30 mg/kg) and 16 
ketamine (100 mg/kg) and positioned in a prototype coil, (birdcage linear coil, 17 
transmit/receive coil, 100 mm long, 55 mm of diameter, tuned at 127.6 MH, Flick 18 
Engineering Solutions BV&Baio G&GE Milwaukee, USA), placed on a support 19 
filled with warm water to preserve mice from hypothermia. For contrast 20 
enhancement 0,05 mmol/kg body weight gadobenate dimeglumine 21 
(MultiHance®) was administered by tail vein injection. The room temperature 22 
during experiments was 23°C, and the mean acquisition time was limited to 35 23 
min, by the spontaneous awakening of mice.  24 
Short localizer sequence was performed and the Field of View (FOV) was 25 
centered on the upper abdomen. 26 
Based on these images, coronal before and after contrast administration T1-27 
weighted and T2-weighted scans were planned and acquired with parameters and 28 
chronological order shown in Table 1. Each pre- and post-contrast sequence lasted 29 
about 7 minutes. The acquisition of all scans lasted about 25 minutes. To obtained 30 
a hepatobiliary contrast phase (HBP) the T1-WI sequences were acquired about 31 




Table 1. MRI imaging protocol parameters at 3 T scanner. The pre- and post-contrast 2 
sequence types are: T1-WI-3D-FSPGR, T1-WI Three Dimensional Fast Spoiled Gradient-3 
echo 1 sequence; T2-WI-FRFSE, T2-WI-Fast Relaxation Fast Spin Echo 2 Sequence. The 4 
repetition time (TR) and the time of echo (TE) are determined by the user to control image 5 
contrast and the weighting of the MR image and are measured in milliseconds (ms). 6 
Bandwidth is a measurement parameter that represents the frequency spectrum (minimum to 7 
maximum processed frequency) of a pulse sequence acquired by a radio frequency system. 8 
The FOV (Field Of View) delineates the area to be imaged. Contrast injection lasted about 9 
1:30 (minutes:seconds, m:s).  Post contrast T1-WI acquisition started 9 minutes after contrast 10 
injection.  11 
 12 
 13 
A total of 40 animals aged 13-18 months were scanned by MRI and checked for 14 
focal lesions in all sequences acquired. 25 mice were scanned once and sacrificed 15 
after the MRI session. The remaining 15 mice were monitored every four weeks 16 
for three months to evaluate lesion growth and complication onset such as rupture 17 














Acquisition Order 1 2 3 
Plane Coronal Coronal Coronal 
TR (ms) 7.6 4700 7.6 
TE (ms) 2.4 84.7 2.4 
Bandwidth 50 31.2 50 
FOV (mm) 10x7.5 10x6 10x7.5 
Thickness (mm) 0.8 1 0.8 




Table 2. Study protocol. 25 mice aged 13-18 months were analyzed by MRI and sacrificed 3 
after image acquisition. 15 mice aged 13-15 months were analyzed by MRI every 4 weeks for 4 
3 consecutive months and then sacrificed for further analysis.  5 
 6 
 7 
We applied a qualitative analysis using a 5-point scale both to T1 and T2WI; the 8 
reader assessed the SI of the representative liver lesion relative to the adjacent 9 
liver parenchyma: 1 = very hypointense, 2 = mildly hypointense, 3 = isointense, 10 
4 = mildly hyperintense, and 5 = very hyperintense (as biliary cysts) (42).   11 
Lesions analyzed on the pre-contrast T1-WI and T2-WI were dimly identified 12 
compared with the liver parenchyma: all lesions were isointense on pre-contrast 13 
T1-WI and showed different signal on T2-WI (hyperintense or isointense, see 14 
below). Imaging acquired after contrast administration allowed to clearly detect 15 
hepatic lesions and to qualitatively distinguish 4 different patterns of contrast 16 









Number of MRI 
analysis performed 
Time of sacrifice 
4 19 NA 1 
Right after image 
acquisition 
10 
17 (7) e 
18 (3) 
NA 1 
Right after image 
acquisition 
9 
15 (4) e 
16 (5) 
NA 1 
Right after image 
acquisition 
2 14 NA 1 
 Right after image 
acquisition 
Total: 25     
4 13 16 
3 
(Every four weeks 
for 3 months) 
Right after last MRI 
analysis 
6 14 17 
3 
(Every four weeks 
for 3 months) 
Right after last MRI 
analysis 
5 15 18 
3 
(Every four weeks 
for 3 months) 
Right after last MRI 
analysis 
Total: 15      
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uptake: isointense, very hyperintense, and very hypointense lesions, and lesions 1 
with a peripheral contrast enhancement (Fig. 6A-E).  2 
These experiments demonstrated that the optimized parameters shown in Table 1 3 
allow precise/high spatial resolution MR imaging of small size murine liver 4 
tumors. In fact, 18 of 40 animals (45%) showed development of focal lesions, 5 
ranging between 1 and 10 mm in diameter, with different combination of MRI 6 
characteristics and mainly detectable on contrast-enhanced T1-WI. We observed 7 




Figure 6. Different enhancement patterns of focal hepatic lesions. LS-G6pc-/- mice were 12 
scanned by MRI. The four different patterns of contrast uptake are shown. (A) Isointense. (B) 13 
Hyperintense. (C) Hypointense.  (D and E) Hypointense lesions with peripheral rim of 14 
contrast enhancement from two different mice are shown. Lesions are indicated by arrows. 15 
 16 
 17 
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Table 3. MRI characteristics of the lesions in G6pc-/- liver. Animals were scanned by MRI 1 
and checked for focal lesions. Nodules were characterized by immunohistochemistry.   2 
aIHCA lesions were isointense on T1-WI before contrast administration and on T2-WI. On 3 
T1_WI, after contrast administration, 12/18 lesions were hyperintense and 6/18 lesions were 4 
hypointense with peripheral rim of contrast enhancement. 5 
bbHCA were isointense on T1-WI before contrast administration, hyperintense on T2-WI, and 6 
hypointense on T1-WI after contrast administration.  7 
cHCC were isointense on T1-WI before contrast enhancement and hyperintense on T2-WI. 8 
On T1- WI, after contrast administration, 2/3 HCC were hypointense and 1/3 was 9 
iso/hypointense.  10 
dUHCA were isointense on T1-WI before contrast enhancement and on T2. After contrast 11 
administration on T1-WI, 2/12 lesions were isointense, 1/12 was hyperintense, 2/12 were 12 
hypointense with peripheral rim of contrast enhancement, and 7/12 were hypointense.  13 
SAA: anti serum amyloid A2; GS: glutamine synthetase.  14 
 15 






Table 4.  Number and type of lesions in LS-G6pc-/- mice.  18 mice showed presence of 5 
focal lesions by MRI analysis. Nodules were analyzed by immunohistochemistry. A total of 6 
41 lesions were characterized.  18/41 tumors were classified as IHCA, 8/41 as bHCA, 12/41 7 
as UHCA, and 3 were HCC. 8 
*One lesion stained positive for SAA and negative for GS; one stained positive for both SAA 9 













of nodules IHCA bHCA UHCA HCC 
1 1   1  
2 1   1  
3 4 3 1   
4 2   2  
5 1 1    
6 4 2 1  1 
7 2 1  1  
8 2 1 1   
9 1    1 
10 1   1  
11 3 1  2  
12 2 1  1  
13 3 2 1   
14 3 1 1  1 
15 5   2* 1 2  
16 4 1 1 2  
17 1 1    
18 1  1   
Total number 
of nodules 41 18 8 12 3 
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3.3 Histology and immunohistochemistry 1 
Mice were sacrificed shortly after the last MRI acquisition.  2 
All livers were macroscopically analyzed for focal hepatic nodules. Before liver 3 
sampling, the orientation of all liver lobes, relative to the longitudinal, transversal, 4 
and sagittal axis of the animal, was marked and the size and location of the 5 
macroscopic tumor nodes was measured with a caliper and correlated to the MRI 6 
findings. Part of the respective liver was then embedded in paraffin and used for 7 
diagnostic procedures. The rest of the liver was saved frozen for further analysis. 8 
All tissue samples were fixed in 10% buffered formalin for 24 hours and paraffin 9 
embedded. For histological analysis four micrometer thick serial sections were 10 
stained with hematoxylin and eosin. Reticulin was visualized by Gomori stain. 11 
Immunostaining was performed with anti-glutamine synthetase (GS; dilution 12 
1:500, Abcam, Cambridge, UK) and anti-serum amyloid A (SAA; dilution 1:100, 13 
Cloud-Clone Corp., Houston, TX, USA) antibodies. Reactions were developed 14 
using DAKO EnVision+ System-HRP (DAB) (DAKO North America Inc. 15 
Carpinteria, California, USA). After immunostaining slides were counterstained 16 
with haematoxylin. Positive and negative controls were included for each run.  17 
 18 
 19 
3.4 Sample collection, histology, and phenotype analyses 20 
Mice were grouped according to their age into 6 groups, from 1 month to 18 21 
months, three months apart. Mice were anesthetized and blood was drawn from 22 
the left ventricle with a syringe. Livers were sectioned, partly frozen for proteomic 23 
analysis and partly fixed in 10% buffered formalin for 24 hours. Formalin fixed 24 
tissue was then processed and from paraffin embedded tissue, four micrometer 25 
thick sections were cut and stained with haematoxylin and eosin for histological 26 
analysis. All animals were phenotypically evaluated as described (22).   27 
Mice were histologically evaluated for liver lesions. Mice showed different degree 28 
of glycogen and lipid accumulation, and six out of twenty LS-G6pc-/- mice 29 






3.5 Sample Preparation 1 
50-100 µg of whole liver tissue was homogenized with a TissueLyser (Qiagen) in 2 
400µl of ice cold lysis buffer (PBS, 4% sodium deoxycholate, 100mM DTT),   3 
incubated for 2-3 hr at 100°C, denaturated and reduced using the FASP Protein 4 
Digestion Kit (Expedeon Inc, Cat. No. 44250). Briefly, the samples were mixed 5 
with 0.3 ml of 8 M urea in 0.1 M Tris/HCl pH 8.5 (UA solution), loaded into the 6 
filtration devices, alkylated in 0.1 ml of 50 mM iodoacetamide in UA solution for 7 
1 h in darkness at room temperature (RT). Samples were digested using 8 
sequentially 1 µg of LysC and 3 µg of Trypsin in 50 mM NaHCO3 solution at 37 9 
°C overnight. Peptides were collected by centrifuging the filters at 20°C for 15 10 
min at 14000 g and the devices were washed twice with 40 µl of 50 mM NaHCO3 11 
and once with 50 µl of 0.5 M NaCl to eliminate the hydrophobic interaction with 12 
the filter.  Each sample digest was desalted on StageTips and analyzed by liquid 13 
chromatography-tandem mass spectrometry (LC-MS/MS). 14 
 15 
3.6 NanoLC setup  16 
Peptide separation was performed with Dionex Ultimate 3000 RSLC nanoSystem. 17 
Samples were first loaded from the sample loop onto a trapping column (2 cm × 18 
100 µm ID,  Acclaim PepMap C18, 2 µm particles, 100 Å pore size; Thermo 19 
Scientific Cat. No. 164564) using the loading solvent (98% H2O and 2% CH3CN, 20 
0.1% formic acid) at a flow rate of 5 µl/min for 5 min. The trapping column was 21 
then switched in-line with the separation column, and peptides were eluted with 22 
increasing organic solvent at a flow rate of 300 nl/min. The peptide separation 23 
was carried out using EASY-Spray column (25 cm x 75 µm ID, PepMap C18, 2 24 
µm particles, 100 Å pore size; Themo Scientific Cat. No. ES803), mounted on the 25 
EASY Spray Ion Source, thermostated at 40 °C. Peptides were separated and 26 
eluted with a multi-steps gradient of 5–30% solution B (80% CH3CN and 20% 27 
H2O, 0.1% formic acid) in 170 min, 30-45% solution B in 35 min. 28 
 29 
3.7 Mass spectrometer setup 30 
The mass spectrometer LTQ-Orbitrap Velos Pro was operated in positive 31 
ionization mode. Single MS survey scans were performed in the Orbitrap, 32 
recording a mass range between 350-1650 m/z with a resolution of 60000. The 33 
 27 
automatic gain control was set at 1.000.000 with a maximal ion injection time of 1 
250 ms. The lock mass option was enabled allowing the internal recalibration of 2 
spectra recorded in the Orbitrap by polydimethylcyclosiloxane background ions 3 
(protonated (Si(CH3)2O)6); m/z 445.120025). The experiments were done in 4 
data-dependent acquisition mode with alternating MS and MS/MS experiments. 5 
The minimum MS signal for triggering MS/MS has been set to 3000 ions, with 6 
the most prominent ion signal selected for MS/MS using an isolation window of 7 
2 Da. The m/z values of signals already selected for MS/MS were put on an 8 
exclusion list for 90 s using an exclusion window size of ±10 p.p.m. In all cases, 9 
one micro-scan was recorded. CID was done with a target value of 3,000 ions in 10 
the linear ion trap, a maximal ion injection time of 100 ms, normalized collision 11 
energy of 35%, a Q-value of 0.25 and an activation time of 10 ms. A maximum 12 
of 20 MS/MS experiments were triggered per MS scan. 13 
 14 
3.8 Bioinformatics procedures and statistical analysis 15 
The schematic representation of the bioinformatics analyses used in the present 16 
study is shown in Figure 1. Raw mass spectrometric data were analyzed with the 17 
MaxQuant software (version 1.5.3.30) (43). A false discovery rate (FDR) of 0.01 18 
for proteins and peptides and a minimum peptide length of 6 amino acids were 19 
required. A time-dependent mass recalibration algorithm was used together with 20 
the Xcalibur lock mass option for recalibration to improve the mass accuracy of 21 
precursor ions (44). MS/MS spectra were searched by the Andromeda search 22 
engine, which is incorporated into the MaxQuant software suite (45) against 23 
Uniprot human database (release 2013_03) combined with 248 common 24 
contaminants and concatenated with the reversed versions of all sequences. The 25 
trypsin was chosen as enzyme specificity. Cysteine carbamidomethylation was 26 
selected as a fixed modification, while protein N-terminal acetylation, methionine 27 
oxidation and deamidation (N, Q), were selected as variable modifications. 28 
Maximally two missed cleavages were allowed. Initial mass deviation for the 29 
precursor ion was up to 7 ppm, and maximum allowed mass deviation for 30 
fragment ions was 0.5 Da. Quantification in MaxQuant was performed using the 31 
built-in label-free quantification algorithm (46), enabling the ‘Match between 32 
runs’ option (time window 2 minutes). 33 
 28 
Comparative proteomics profiling was performed by Principal Component 1 
Analysis (PCA) implemented in ClustVis online resource (47). Time-course 2 
algorithm was used across the 6 experimental time points to identify differentially 3 
expressed proteins. Time-course analysis used the Significance Analysis of 4 
Microarrays method (48) implemented in the Web-enabled and Cross-platform 5 
SAM via Shiny (https://github.com/MikeJSeo/SAM). For building the SAM 6 
interactive web app straight from R, we used the Shiny R package setting up a two 7 
classes, unpaired, time course analysis with slope function as summary measure 8 
for each time course.  The slope is useful for finding proteins with a consistent 9 
increase or decrease over time.  For two class-unpaired data, SAM summarizes 10 
each time series by a slope. Then the slopes are compared across the two groups. 11 
Thus a positive SAM score means that the slopes are larger (on average) in the 12 
group 2 than in the group 1; the opposite is true for a negative. A positive SAM 13 
score could mean that the slopes are positive in both groups, but larger in the group 14 
2, or they could both be negative but less negative in group 2, or finally they could 15 
be negative in group 1 and positive in group 2.  16 
Gene ontology (GO) and KEGG analyses were carried out on selected groups of 17 
proteins using the STRING-DB software (49). An FDR lower than 0.05 identified 18 
significantly enriched ontology terms and pathways.  19 
STRING-DB software was also used to evaluate protein-protein interaction (PPI) 20 
network from selected groups of proteins. PPI enrichment p value was used to 21 
assess whether a group of proteins have more interactions among themselves than 22 
what would be expected from a random set of proteins of similar size, drawn from 23 
the genome. We considered significantly a PPI enrichment p value lower than 24 
0.05.  25 
Statistical calculations were performed using Prism for Macintosh V6 (GraphPad 26 
Software Inc., La Jolla, CA). 27 
 28 
3.9 Gene set enrichment analysis 29 
We used GSEA (50) to evaluate the enrichment of known biological processes 30 
and pathways in LS-G6pc-/- mice. We carried out the analysis on all available 31 
protein symbols. GSEA calculates an enrichment score (ES) and normalized 32 
enrichment score (NES) for each gene set and estimates the statistical significance 33 
of the NES by an empirical permutation test using 1.000 gene permutations to 34 
 29 
obtain the nominal p-value. However, when multiple gene sets are evaluated, 1 
GSEA adjusts the estimate of the significance level to account for multiple 2 
hypothesis testing. To this end, GSEA computes the False Discovery Rate q-value 3 
(FDR q-value) measuring the estimated probability that the normalized 4 
enrichment score represents a false positive finding (50). The gene sets used in 5 
the analysis belong to the Hallmark (H), KEGG (C2.CP.KEGG) and Gene 6 
Ontology (C5.GO) collections of the Molecular Signature Database (MSigDB) 7 
v6.2 database (51,52). A gene set with nominal p value lower than 0.05 and FDR 8 
q-value lower than 0.25 is considered significant. 9 
 10 
 11 
3.10 Mouse plasma samples 12 
Blood was collected from the heart at the time of the sacrifice, in EDTA tubes and 13 
was centrifuged at 2100 rpm for 10 minutes at room temperature (RT) to collect 14 
plasma. Plasma was stored at -80° C or used immediately for exosome isolation. 15 
The samples were collected at different time-points (1-3, 4-6, 7-9, 10-12, 13-15 16 
months) that reflect different stages of disease progression.   17 
 18 
3.11 Exosome isolation and miRNA purification from plasma 19 
Exosomes isolation and RNA extraction were performed with the exoRNeasy 20 
Serum/Plasma Midi kit (Qiagen Italia, Milan, Italy). 100 µl of plasma were 21 
centrifuged at 16,000 x g at 4°C to eliminate cellular debris. Supernatants were 22 
then mixed with one volume of XBP binding buffer, loaded onto the exoEasy spin 23 
column, and spun at 500 x g 1 minute at RT. Next, 3.5 ml of XWP Washing Buffer 24 
was added to the filter column and spun at 5,000 x g for 5 minutes at RT. The spin 25 
column was transferred to a new collection tube and centrifuged at 5,000 x g for 26 
5 minutes at RT after the addition of 700 µl of QIAzol to the membrane, to collect 27 
the lysate. Next, RNA extraction was performed according to the manufacturer’s 28 
instructions. Quality control and miRNA evaluation were performed on the 29 
Agilent 2100 Bioanalyzer, using the Small RNA Assay (Agilent Technologies 30 




3.12 Quantitative Real Time PCR (qRT-PCR) 1 
Exosomal miRNA were analyzed by the TaqMan Array Card Technology. 2 
miRNA were reverse transcribed with the TaqManâ microRNA Reverse 3 
Transcription Kit, using the MegaplexTM RT primers Rodent Pool A (Thermo 4 
Fisher Scientific, Monza, MB, Italy). Pre-amplification of cDNA was performed 5 
with TaqManâ PreAmp Master Mix and MegaplexTM Pre-Amp primers Rodent 6 
Pool A. The pre-amplification product was diluted according to the 7 
manufacturer’s instructions and used to perform microRNA profiling on the 8 
ViiATM 7 Real-Time PCR System. Briefly, 9 µl of the diluted pre-amplified 9 
product was mixed with 450 µl TaqManâ Universal Master Mix II, No UNG 10 
(Thermo Fisher Scientific, Monza, MB, Italy) and 441 µl of nuclease-free water. 11 
100 µl of the PCR reaction mix was dispensed into each well of the TaqManâ 12 
Array Rodent microRNA A card (Thermo Fisher Scientific, Monza, MB, Italy), 13 
enabling the quantification of 381 miRNA. 14 
 15 
3.13 Bioinformatic procedures and statistical analysis 16 
We designed ExoPIPE, a new bioinformatic pipeline implemented in R, for the 17 
analysis of exosomal miRNA (exo-miR) expression measured by quantitative 18 
real-time PCR technology.  The pipeline used functions implemented in both 19 
published R packages (53,54) and R modules implemented in our laboratory. 20 
ExoPIPE is composed by the following main modules: data preprocessing, Cycle 21 
Threshold (CT) filtering, data normalization, data imputation, and feature 22 
selection. 23 
Data preprocessing module retrieves the tab separated text file containing CT 24 
values and any feature meta-data from every high-throughput qPCR experiment 25 
and creates a single raw data file containing the CT value of each well on the card, 26 
as well as information about the quality of the wells (e.g. experiment 27 
failure=TRUE/FALSE) (53).  CT filtering module assigns a category (i.e. 28 
underdetermined, unreliable) to a CT value based on the different criteria and it 29 
filters out CT values based on their category (53). For instance, we categorized as 30 
unreliable any CT value higher than 32 in accordance with the literature (55), any 31 
CT value lower than 14, or undergoing an experiment failure as recommended by 32 
the manufacturer guidelines.   33 
 31 
Data normalization module reduces unwanted technical variation in the data using 1 
different methods including rank invariant, geometric mean, and quantile (53). 2 
Global mean method (GM) is a normalization method, which uses the mean 3 
expression value of a sample as candidate normalizer (56). GM is a recognized 4 
method of normalization for microRNA RT-qPCR data, but it is not implemented 5 
in the HTqPCR package at the moment. So, we extended HTqPCR implementing 6 
GM to normalize exo-miR expression profiles. Cumulatitve distribution of 7 
miRNA coefficient of variation values and Kolmogorov-Smirnov test assessed the 8 
performance  of the GM normalization, as it was already shown in the literature 9 
(56). Data imputation module filters out any miRNA whose expression was 10 
undetermined or unreliable (NA) for a pre-specified number of samples and 11 
imputes the remaining NAs with an appropriate method. Data filtering has a 12 
dedicated function in the HTqPCR package (53). Whereas, NA values were 13 
imputed with the lowest expression value of the respective miRNA minus one 14 
log2 unit (55). To maintain the bias introduced with imputation low, only exo-15 
miRs detected in at least 95% of samples were included in the analysis. 16 
RankProd R package (57) has been used to identify differentially expressed 17 
miRNAs. miRNA with fold change >1.5, p-value<0.05 and FDR<0.05 are 18 
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4. RESULTS 1 
 2 
4.1 Characterization of hepatic focal lesions in LS-G6pc-/- mice 3 
LS-G6pc-/- mice livers were histologically examined. Liver parenchyma showed 4 
the classical histological features of GSD1a (20,22).  5 
All HCA were histologically examined and immunostained for pathological 6 
classification. Histological analysis of HCA of LS-G6pc-/- mice showed that they 7 
were un-encapsulated nodules composed of hepatocytes with no or little atypia 8 
and with no or few intralesional portal tracts (Fig. 7A, a, d, and g). 9 
Anti-GS, to identify bHCA, high risk adenomas, and anti-SAA antibodies, to 10 
identify IHCA, were used. For GS, only a strong and diffuse cytoplasmic staining 11 
was considered positive and staining intensity was comparable to the staining in 12 
normal liver in the centrilobular, perivenular hepatocytes. SAA marked both 13 
IHCA hepatocytes with granular cytoplasmic staining and amyloid deposits in 14 
vascular and/or sinusoidal spaces. We previously reported that 90% of LS-G6pc-15 
/- mice develop amyloidosis by 12 months of age (22).  16 
HNF1alpha-mutated HCA have not been identified in GSD-related HCA (19) and 17 
therefore silenced FABP1 was not searched for in LS-G6pc-/- mice liver tumors. 18 
18 nodules stained positive for SAA and negative for GS, and were identified as 19 
IHCA (Fig. 7A,b and c), 8 nodules stained negative for SAA and positive for GS 20 
and were identified as high risk bHCA (Fig. 7A,e and f), and 12 nodules were 21 
negative for both SAA and GS and were classifies as UHCA (Fig. 7A,h and i). 22 
Moreover, three lesions were well differentiated HCC (Fig. 7B,a), characterized 23 
by positive staining for GS (Fig. 7B,b) and loss of reticulin framework (Fig. 7B,c). 24 
These results, summarized in Table 4, are in agreement with the molecular 25 







  2 
Figure 7. Immunoclassification of adenomas in LS-G6pc-/- mice. LS-G6pc-/- mice livers 3 
were fixed with 10% formalin and paraffin embedded. Serial sections were stained with 4 
hematoxilin/eosin (H&E) or treated with anti-serum amyloid (SAA) or anti-glutamine 5 
synthetase (GS) antibody. (A) Histological features and immunohistochemistry analysis of 6 
liver adenomas in LS-G6pc-/- mice. H&E-stained section of an IHCA (a). An IHCA nodule 7 
shows diffuse positivity for SAA within the lesion, while the surrounding parenchyma is 8 
negative except for perivascular amyloid deposition (b). The same nodule shows negativity 9 
for GS antibody, while the surrounding non-lesional parenchyma shows normal GS staining 10 
in perivascular hepatocytes (c). H&E-stained section of a bHCA (d). A bHCA nodule is 11 
negative for SAA (e) but shows strong positivity for GS within the lesion, while the 12 
surrounding non-lesional parenchyma shows normal zonation of expression in perivascular 13 
hepatocytes (f). H&E-stained section of an UHCA (g). An UHCA nodule is negative for both 14 
SAA (h) and GS (i). (a-c): 10x magnification; (d-i): 4x magnification. (B) Histological 15 
features and immunoexpression of GS in a liver carcinoma. (a) H&E-stained section of a 16 
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nodule showing atypia. (b) Strong and diffuse positivity to GS within the lesion. (c) An HCC 1 
section stained with Gomori stain, showing loss of reticulin framework typical of malignancy. 2 




4.2 Correlation between MR signals and immunohistological analysis in 7 
livers of LS-G6pc-/- mice 8 
To characterize the hepatic lesions detected in LS-G6pc-/- mice and correlate MRI 9 
features to the different adenoma subtypes, a total of 40 animals aged 13-18 10 
months were scanned by 3 T clinical MRI and checked for focal lesions in all 11 
sequences acquired. A total number of 41 liver lesions were detected in 18 out of 12 
the 40 animals analyzed with an incidence of 45%. 25 mice were scanned once 13 
and sacrificed immediately after MRI acquisition.  The remaining 15 mice were 14 
monitored every four weeks for three months to evaluate lesion growth and 15 
complication onset such as rupture and bleeding (see Table 2), as described below. 16 
MRI identified 4 different patterns of contrast uptake after contrast administration: 17 
isointense, very hyperintense, and very hypointense lesions, and lesions with a 18 
peripheral contrast enhancement. 19 
All typical IHCA were isointense on pre-contrast T1-WI and on T2-WI (Fig. 8A 20 
and C). On T1-WI after contrast administration, 11/18 (61%) of the IHCA showed 21 
a very hyperintense signal compared to the surrounding liver (Fig. 8B), while 6/18 22 
(33%) showed a peripheral rim of contrast enhancement and central hypointensity 23 
(Fig. 6D and E). We observed one case of adenoma (1/18, 6%) featuring high 24 
expression of both SAA and GS (data not shown). This lesion was isointense on 25 
pre-contrast T1-WI (Fig. 8D) and, after contrast administration, was hyperintense 26 
and characterized by the presence of a faint hypointense central scar (Fig. 8E and 27 
E’). On T2-WI, the lesion was hypointense while the central scar was hyperintense 28 
(Fig. 8F and F’).   29 
None of the bHCA, featuring GS overexpression, showed hyperintensity 30 
compared to the surrounding liver in the hepatocyte phase or peripheral rim of 31 
contrast enhancement after contrast sequences. 5/5 lesions (100%) were very 32 
hypointense after contrast administration on T1-WI and mildly hyperintense on 33 
T2-WI (Fig. 8G-I). 34 
 35 
All well-differentiated HCC (3/3) were mildly hyperintense on T2-WI, isointense 1 
on T1-WI before contrast, and very hypointense (2/3) (Fig. 9J-L) or mildly 2 
hypo/isointense (1/3), after contrast administration (not shown). 3 
UHCA showed all 4 different contrast enhancement patterns: the majority (7/12) 4 
were very hypointense lesions, 2/12 isointense, 1/12 very hyperintense and 2/12 5 
with peripheral ring of contrast enhancement. Fig. 8M-O show representative 6 
images of a very hypointense UHCA lesion. All UHCA lesions were isointense 7 
on T2-WI (Fig. 8O), differently from bHCA and HCC, which are mildly 8 
hyperintense (Fig. 8I and L).  9 
These results, summarized in Table 3, indicate that our MRI protocol can be used 10 
to identify HCA and to distinguish high-risk from low-risk adenomas. MRI could 11 
therefore represent a less invasive tool for early diagnosis and classification of 12 





Figure 8. MRI of various subtypes of liver lesions in LS-G6pc-/- mice. LS-G6pc-/- mice 3 
were scanned by MRI and checked for focal lesions in all acquired sequences. (A-C) A typical 4 
IHCA is isointense on T1-WI, before contrast administration (c.a.) (A), and on T2-WI (C), 5 
while on T1-WI, after c.a., it shows areas of hyperintensity compared to the surrounding liver 6 
(B, arrow).  (D-F) An atypic IHCA is isointense on T1-WI, before c.a., (D) but hyperintense, 7 
after c.a.  (E, arrow) and characterized by the presence of a faint hypointense central scar (E’), 8 
mildly hyperintense on T2-WI (F, arrow and F’).  (G-I). A bHCA lesion is isointense to the 9 
liver parenchyma on T1-WI before c.a. (G), hypointense on contrast enhanced T1-WI (H, 10 
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arrow) and mildly hyperintense on T2-WI (I, arrow). (J-L) The HCC shown is isointense on 1 
T1-WI acquired before c.a. (J, arrow), while it shows prominent  hypointensity on T1-WI 2 
after c.a. (K, arrow) and slightly hyperintense on T2-WI (L, arrow). (M-O) A UHCA lesion 3 
is isointense on T1-WI before c.a. (M), hypointense on T1-WI, after c.a. (N, arrow). The 4 






4.3 Monitoring of hepatic lesions 11 
In order to characterize the evolution and growth of the liver lesions in LS-G6pc-12 
/-  mice, we performed periodic MRI on 15 LS-G6pc-/- mice aged 13-15 months.   13 
The animals were monitored every 4 weeks for three months and the tumor growth 14 
was analyzed by measuring lesion diameter using the off-line workstation. Tumor 15 
measurement was done on the basis of T1-weighted contrast-enhanced scans. 16 
Seven mice showed presence of nodules. 17 
Time-dependent monitoring demonstrated that hyperintense lesions (n=4) on 18 
contrast enhanced T1-WI, without evidence of hyperintensity on T2-WI, had a 19 
slow growth rate. All these lesions were identified by immunohistochemistry as 20 






Figure 9. Growth characteristics of IHCA.  Tumor measurement in LS-G6pc-/- mice was 3 
done on the basis of T1-weighted contrast-enhanced scans. (A) A hyper-intense lesion was 4 
detected on T1-WI after contrast administration (c.a.) at the first MRI evaluation.  (B) One 5 





At the first MRI evaluation one of these mice showed 2 very hypointense  nodules 11 
on T1-WI after contrast administration (Fig. 10A). Interestingly, these 2 lesions 12 
showed different signals on T2-WI imaging: the smaller one was, at the first MRI 13 
examination, isointense (Fig. 10B, arrow) while the bigger one was mildly 14 
hyperintense (Fig. 10B, dashed arrow).   15 
After one month, one of the lesions had only slightly changed in size (Fig. 10C, 16 
arrow) but had become mildly hyperintense on T2-WI (Fig. 10D, arrow), while 17 
the other lesion had significantly increased its size (Fig. 10C, dashed arrow), 18 
remaining hyperintense on T2-WI (Fig. 10D, dashed arrow) with an internal cystic 19 
degeneration.   20 
At the third MRI evaluation, also the smaller lesion showed 50% increase in size, 21 
suggesting a fast growth rate (Fig. 10E, arrow). Both lesions remained mildly 22 
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hyperintense on T2-WI (Fig. 10F) and were classified by immunohistochemistry 1 
as UHCA.  2 
These findings support the hypothesis that lesions hypointense on HPB phase and 3 
mildly hyperintense on T2-WI are rapidly growing tumors. This preliminary 4 
experiment underlies the need of further studied to better understand the real 5 
biological behavior of UHCA. 6 
A third lesion, hyperintense on post contrast T1-WI (Fig. 10E, arrowhead) was 7 
visualized at this stage and characterized as an IHCA. 8 
 9 
 10 
Figure 10. Time-dependent monitoring of hepatic lesions. LS-G6pc-/- mice were monitored 11 
every 4 weeks for three months and the tumor growth was analyzed by measuring lesion 12 
diameter using the off-line workstation. At the first MRI evaluation (A,B) 2 lesions were both 13 
hypointense  on contrast enhanced T1-WI but showed different signals on T2-WI imaging: 14 
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the small nodule was hypointense (arrow) while the bigger nodule was hyperintense (dashed 1 
arrow). After one month (C,D), one lesions (arrow) had slightly changed in size and had 2 
become hyperintense on T2-WI, while the other lesion (dashed arrow) had rapidly increased 3 
in size and presented with a large central cystic portion that can denote a necrosis area (bright 4 
signal intensity).  At the third MRI evaluation (E,F), also the small lesion (arrow) showed a 5 
size increase of 50%, suggesting a high growth rate. Both lesions were ipointense on T1-WI 6 
after c.a. and hyperintense on T2-WI. They were classified by immunohistochemistry as 7 
UHCA. A third lesion, hyperintense on contrast enhanced T1-WI (arrowhead) and isointense 8 































4.4 Expression profiling of hepatic proteins in LS-G6pc-/- and WT mice 1 
To identify potential biomarkers and key biological processes associated with 2 
liver degeneration in GSD-1a, we analyzed the proteomic expression profile of 3 
LS-G6pc-/- and wild type (WT) mice. The flowchart summarizing the main steps 4 








Figure 11. Schematic representation of the whole bioinformatic strategy used in the 13 
study  14 
The protein expression profile of 18 WT and 20 LS-G6pc-/- mouse livers was measured by 15 
LC-MS/MS. Pathological evaluation of the livers assessed the presence of hepatic adenomas 16 
within the entire set of LS-G6pc-/- mice samples.  Gene set enrichment analysis (GSEA) 17 
assessed the enrichment of curated protein-encoding gene sets in the groups of LS-G6pc-/- 18 
mice characterized by the presence\absence of hepatic adenomas, and in the groups of mice 19 
characterized by the presence\absence of GSD-1a disease. The expression profile of LS-G6pc-20 
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/- and WT mice over 6 distinct age groups was compared using SAM. Analysis identified two 1 
sets of differentially expressed proteins including proteins with a significant positive and 2 
proteins with a significant negative slope. The two sets of significantly differentially 3 
expressed proteins were used for network and pathway analyses. Network analysis evaluated 4 
the presence of a potential functional connection among the significant proteins. Pathway 5 
analysis identified the most significantly altered biological processes and pathways.    6 
 7 
 8 
Mice were divided into six groups according to their age (Table 5). A total of 20 9 
LS-G6pc-/- and 18 WT mice were analyzed. All LS-G6pc-/- mice utilized were 10 
characterized for pathological manifestations and found to display all the features 11 
already described for this murine model of GSD-1a (22), including hepatomegaly 12 
and glycogen accumulation (data not shown). Six LS-G6pc-/- mice developed at 13 
least one HCA. None of the WT mice developed liver disease, as expected. 14 
Livers were profiled by a proteomic approach based on high-resolution mass 15 
spectrometry (HRMS) coupled with liquid chromatography techniques. We 16 
obtained a total of 57893 peptides that mapped to 4763 unique mouse gene 17 
symbols. Of these, 4138 significantly expressed proteins were quantified and 18 
organized in a dataset.  19 
 20 
      
        
Group 
Age 
(months) LS-G6pc-/- HCA WT HCA   
1       1-3 3 0 3 0   
2       4-6  3 0 3 0   
3       7-9  3 0 3 0   
4       10-12  3 1 3 0   
5       13-15  3 3 3 0   
6       16-18  5 2 3 0   
        
Table 5 - Animals analyzed. Data are relative to the 20 LS-G6pc-/- mice and 18 wild type 
mice in the data set.   
  
   




4.5 GSEA reveals the enrichment of hypoxia-related proteins in the 1 
expression profile of LS-G6pc-/- mouse livers  2 
Gene set enrichment analysis (GSEA) (50) is a computational technique that 3 
determines whether an a priori defined set of genes (gene set) shows statistically 4 
significant concordant expression differences between two biological states. 5 
Seven distinct collections of gene sets are publicly available in MSigDB 6 
database (51,52). We carried out GSEA between 20 LS-G6pc-/- and 18 WT 7 
protein expression profiles using the hallmark collection composed by 50 8 
curated gene sets that represent well-defined biological states or processes, the 9 
C5.BP collection composed by 4436 gene sets derived from Gene Ontology 10 
database, and the C2.CP.KEGG collection composed by 186 gene sets derived 11 
from the KEGG pathway database.  To use MSigDB collections, protein 12 
symbols have been converted into the corresponding gene symbols.  GSEA 13 
identified 71 significantly unregulated gene sets in the expression profile of the 14 
LS-G6pc-/- compared to WT groups of mice (Nom p-value<0.05 and FDR q-15 
value < 0.25, data not shown). The list included gene sets related to the response 16 
to hypoxia and GSD-1a disease such as HALLMARK_HYPOXIA, 17 
HALLMARK_GLYCOLYSIS, and KEGG_ PYRUVATE_METABOLISM, 18 
GO_FATTY_ACID_BIOSYNTHETIC_PROCESS, and 19 
GO_GLUCOSE_6_PHOSPHATE_METABOLIC_PROCESS. 20 
HALLMARK_HYPOXIA was the most significant hypoxia related gene sets 21 
(NES 2.07, Nom p- value=0.0 and FDR q-value=0.001, data not shown). The 22 
enrichment plot (Figure 12A) and the heat map (Figure 12B) show a graphical 23 
view of the enrichment score and the proteins expression value of the 24 
HALLMARK_ HYPOXIA gene set between the LS-G6pc-/- and the WT groups 25 
of mice. Among the 24 genes that mostly contributed to the enrichment of the 26 
HALLMARK_HYPOXIA gene set (leading edge subset), several enzymes 27 
involved in the lactic acid production by anaerobic glycolysis are upregulated in 28 
the livers of LS-G6pc-/- mice, such as PFKL, TPI1, GAPDH, PKLR, LDHA and 29 
PDK1.  30 







Figure 12. GSEA of HALLMARK_HYPOXIA gene set in LS-G6pc-/-  mice 4 
(A) Enrichment plot of the HALLMARK_HYPOXIA gene set showing the hypoxic 5 
phenotype of LS-G6pc-/- mouse liver. To use MSigDB collections, protein symbols have 6 
been converted into the corresponding gene symbols.  Genes were ranked by level of up or 7 
downregulation comparing 20 LS-G6pc-/- and 18 WT mice.  The enrichment score is 8 
calculated by walking down a list of genes ranked by their correlation with the phenotype, 9 
increasing a running sum statistic when a gene in that gene set is encountered (each black 10 
vertical line underneath the enrichment plot) and decreasing it when a gene that isn’t in the 11 
gene set is encountered. The enrichment score is the maximum deviation from zero 12 
encountered in the walk. (B) Heat map visualization of the proteins belonging to the 13 
HALLMARK_HYPOXIA gene set showing a clear differential expression of the leading 14 
edge subset between LS-G6pc-/-  and WT mice. The genes that mostly contributed to the 15 
enrichment of a gene set, named leading edge subset, are indicated by brackets. A gene set 16 
with nominal p value lower than 0.05 and FDR q-value lower than 0.25 was considered 17 




4.6. Time-course analysis highlights age-dependent modulation of protein 1 
expression in LS-G6pc-/- mouse livers  2 
Age dependent modulation of protein expression may be instrumental to find 3 
biomarkers of LS-G6pc-/- mouse liver disease.  We carried out Principal 4 
Component Analysis (PCA) of the proteomic profile of LS-G6pc-/- and WT mice 5 
grouped by age to highlight any similarities or differences between them (Figure 6 
13). PCA revealed a clear separation between LS-G6pc-/- and WT mice in all age 7 
groups. Furthermore, we observed modulation of the proteomic profiles of both 8 
LS-G6pc-/- and WT mice across age groups. 9 
Significance Analysis of Microarrays (SAM) is a statistical technique to perform 10 
differential expression analysis on different kinds of data including time-course 11 
data. Analysis summarizes each time course by a slope and treats the summarized 12 
data in the same way as it treats a two-class differential expression problem. The 13 
slope analysis is useful for finding proteins with a consistent increase or decrease 14 
expression over time on the basis of a delta value. Different delta values are 15 
associated with different false discovery rates (FDR) by SAM. We used the 16 
expression profile of LS-G6pc-/- and WT mice grouped by age to perform a time-17 
course analysis using SAMR. We set up a delta value of 0.49 to maintain the false 18 
discovery rate below 15%. SAM analysis identified 1243 proteins with a 19 
significant differential slope between LS-G6pc-/- and WT mice. Among these 20 
proteins, 701 had a positive slope in LS-G6pc-/- (Score (d)>0 and q-value 21 
(%)<15) and 542 had a negative slope in LS-G6pc-/- with respect to WT mice 22 
(Score (d)<0 and q-value (%)<15 (Figure 14A). Heat map evidenced a clear 23 
opposite expression trend of these proteins as mice grew older, suggesting an 24 
age- dependent alteration of these proteins in LS-G6pc-/- mice and validating in 25 







Figure 13. PCA of the LS-G6pc-/- and WT mice grouped by age 4 
 An age group defines a subset of mice of a pre-specified range of ages expressed in months.  5 
Each plot identifies a distinct age group. PCA used the whole proteomic profile of each 6 
sample.  Axes in the PCA plot are relative to the two principal components with the largest 7 
variance. Ellipse around a group of samples indicates the estimated region where a new 8 
observation from that group would fall in with a certain probability (i.e. 95%). Each point 9 
indicates a sample and is labeled with the sample identifier. LS-G6pc-/- and WT mice are 10 








Figure 14. Time course analysis reveals an age dependent modulation of protein 3 
expression  4 
(A) SAM plot generated by SAM tool in the time course analysis. A delta value of 0.49 was 5 
applied to identify significant differentially expressed proteins. Significant positive slope 6 
proteins are illustrated in red and significant negative slope proteins are depicted in green.  7 
(B) Heat map of the significant differentially expressed proteins between LS-G6pc-/- and WT 8 
mice (lines) grouped by age and mouse type (columns). For each protein, mouse model type, 9 
and age group, the heat map displays the average expression of the protein among the samples 10 
of that particular type and age group. The expression data of each protein have been scaled 11 
and are represented by pseudo-colors. Red color corresponds to high level of expression and 12 
blue color corresponds to low level of expression. Brackets depict significant positive and 13 








4.7. Network and pathway analyses reveal activation of specific biological 1 
processes associated with increased progression of liver disease 2 
Network analysis can help to identify biologically relevant substructures within a 3 
group of proteins (49).  We carried out a network analysis using STRING-DB 4 
based on the proteins identified in SAM analysis. Displaying a protein as a node 5 
and a functional association between two proteins as an edge, we built one 6 
network for the proteins with a significant positive slope and another network for 7 
the proteins with a significant negative slope.  Visual inspection of the network 8 
for the proteins with a significant positive slope identified one dense cluster 9 
connecting the majority of the proteins in this group (Figure 15A), whereas, 10 
inspection of the network of proteins with a significant negative slope identified 11 
several sparse, but connected, clusters linking a restricted number of proteins 12 







Figure 15. Association network of the proteins identified with the time-course analysis. 20 
The plot was generated by STRING-DB software. A network node represents a protein. An 21 
edge between two proteins represents the predicted functional association between them.  22 
 49 
Associations are derived from high-throughput experimental data, from the mining of 1 
databases and literature, and from predictions based on genomic context analysis.  The 2 
thickness of the line indicates the degree of confidence prediction of the association.  Only 3 
associations with a high degree of confidence of 0.7 are displayed in the plot. (A) Association 4 
network among proteins with a significant positive slope. (B) Association network among 5 
proteins with a significant negative slope. The association between two proteins can mean 6 
direct physical binding, but can also mean indirect interaction such as participation in the 7 
same metabolic pathway or cellular process. Thus, the presence of clusters of associations 8 





These results highlighted the presence of two distinct networks of proteins 14 
characterized by a different number of clusters and density. Both networks 15 
exhibited significantly more interactions than expected by chance (Protein-protein 16 
interaction enrichment p-value < 1.0e-16) suggesting a potential biological link 17 
among subsets of proteins identified in the SAM analysis.  18 
We performed a pathway analysis on the two lists of proteins using STRING-DB 19 
to assess this biological connection. Pathway analysis based on Gene Ontology 20 
processes and KEGG pathways showed a significant enrichment of 451 GO 21 
biological processes and 107 KEGG pathways (data not shown). In particular, we 22 
observed an enrichment of proteins involved in non-alcoholic fatty liver disease, 23 
mitochondrial activity, inflammation response, and immune response (FDR q-24 
value<0.05, Table 6), indicating that, as LS-G6pc-/- mice grew older, activation of 25 
specific biological processes associated with increased progression of liver 26 








Table 6. Summary of the biological processes and pathways significantly modulated 3 
over time. aConcise names summarizing a group of significant GO biological processes and 4 
KEGG pathways.  GO and KEGG enrichemnt analysis was carried outon proteins whose 5 
slope of expression in  LS-G6pc-/- compared with WT mice was significantly modulated. 6 
bOfficial identifier of a GO biological process or KEGG pathway.   7 
cOfficial name of a GO biological process or KEGG pathway.    8 
dNumber of proteins of a GO biological process or KEGG pathway whose slope of expression 9 
was significantly modulated in LS-G6pc-/-.    10 
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eFDR q-value estimates the significance of the enrichemnt of a biological process or a 1 
pathway. FDR q-value <= 0.05 are considered acceptable.       2 
f Positive or Negative indicates the type of slope of the protein involved in a process or a 3 
pathway.         4 
g Name of the ontology defining a biological process or pathway. GO BP stands for gene 5 
ontology biological process. KEGG stands for Kyoto Encyclopedia of Genes and Genomes. 6 
  7 
       8 
Among the proteins with a significant slope in LS-G6pc-/- mice, we observed 9 
modulation of several proteins involved in glucose and lipid metabolism. While 10 
some of these proteins are consistent with an enhanced hepatic glycolytic 11 
pathway, others are consistent with an enhanced gluconeogenesis, suggesting that 12 
both metabolic pathways are activated. Compared to control mice, livers of older 13 
LS-G6pc-/- mice display downregulation of several components of oxidative 14 
phosphorylation (OXPHOS) process (both of the respiratory chain complexes and 15 
ATP synthase), and upregulation of several proteins involved in fatty acid and 16 
cholesterol biosynthesis. In addition, older LS-G6pc-/- mice show upregulation of 17 
aconitase, amino transferase (AT) and isocitrate dehydrogenase (IDH1) involved 18 





Table 7. Proteins involved in glucose and lipid metabolism modulated in LS-G6pc-/- mice. 1 
aProtein symbol retrieved from UNIPROT database.   2 
bApproved name of the protein. cPositive or Negative indicates the type of slope associated 3 
with the protein. dOfficial name of the GO biological process involving the protein. Data are 4 
listed in alphabetic order.   5 
 6 
 7 
4.8. GSEA analysis indicates acute inflammatory and immune responses in 8 
liver from LS-G6pc-/- mice with HCA 9 
To shed light on the molecular mechanisms underlying the development of HCA 10 
in LS-G6pc-/- livers, we performed a GSEA analysis comparing the expression 11 
profile of LS-G6pc-/- mice that developed at least one HCA with those that did 12 
not. For the analysis we used the hallmark, the C2.KEGG, and the C5.GO.BP 13 
collections of the MSigDB database.  14 
GSEA identified 148 significantly enriched gene sets in LS-G6pc-/- mice with 15 
adenomas (Nom p-value<0.05 and FDR q-value < 0.25, data not shown). 16 
Among the gene sets identified, the most represented processes included 17 
complement and coagulation cascade, acute-phase response, acute inflammatory 18 
response, and immune response.  In the complement and coagulation protein sets, 19 
we found two proteins, which play a central role in the activation of the 20 
complement system, specifically the component C3 and the component C5 (Table 21 




Table 8. Proteins involved in inflammatory and immune response modulated in LS-26 
G6pc-/- mice with adenoma. aProtein symbol retrieved from UNIPROT database. Protein 27 
symbols are listed in alphabetic order. bApproved name of the protein. cSignificantly enriched 28 
biological process assoociated with the protein by GSEA.      29 
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Among the proteins associated with the inflammatory and immune response 1 
processes, some were typical of macrophages polarized towards the alternatively 2 
activated M2 phenotype   such as mannose receptor C-type 1 (CD206), a type 1 3 
membrane lectin receptor that mediates the endocytosis of glycoproteins by 4 
macrophages; arginase 1, (ARG1), that catalyzes the hydrolysis of arginine to 5 
ornithine and urea; and the scavenger receptor MSR1, (CD163), an acute phase-6 
regulated receptor involved in clearance and endocytosis of 7 
hemoglobin/haptoglobin complexes by macrophages. Moreover, binding lectins 8 
A (MBL1) and C (MBL2) and STAT6 were found upregulated in the liver of LS-9 
G6pc-/- mice with HCA, suggesting accumulation of M2-polarized macrophages 10 
(Table 8) (52).   Therefore, different proteins involved in the process of tissue 11 
inflammation and macrophage polarization, and thus associated with tumor 12 
progression, were identified. 13 
These results are compatible with the pathologic environment represented by 14 
hypoxia, which was reported to affect macrophage polarization towards M2 15 
phenotype both in rodents and in humans (58,59).  16 
 17 
4.9. Analysis of exosomal miRNA extracted  from plasma of LS-G6pc-/- 18 
mice.  19 
Exosomes from 100 µl of plasma of 45 LS-G6pc-/- mice and relative controls were 20 
isolated.  Total RNA was extracted and the presence of miRNA was evaluated by 21 
capillary electrophoresis to ensure a sufficient retrieval of material for the 22 
following analyses. The difference between a suitable and an inadequate miRNA 23 
profile is shown in figure 16A and B: a significant miRNA fraction is represented 24 
by different peaks in the region between 10-50 nucleotides, corresponding to 25 
miRNA molecules. The RNA samples with a flat profile in this region failed the 26 
quality control and were discarded from subsequent analyses.  27 
RNA samples were reverse transcribed, pre-amplified, and used to set up a rodent 28 
microRNA array card that allowed measuring the expression of 381 targets for 29 





Figure 16. Small RNA profile in LS-G6pc-/- mice.  The electropherogram derived from 3 
the capillary electrophoresis displays the number of nucleotides (6 to 150) on X axis and 4 
the dye fluorescence on the Y axis. Plasma was obtained from LS-G6pc-/- mice plasmas. 5 
The profile of the RNAs from 6 to 150 nucleotides (nt) is shown and it is measured as 6 
Fluorescence Dye Units (FU). The region between 6 to 40 nucleotides, indicated by the 7 
dashed vertical lines, includes the miRNA fraction. Here, it is shown the difference between 8 
a suitable (A) and an inadequate miRNA profile (B). 9 
 10 
4.10. Data normalization 11 
We performed an accurate statistical analysis of the raw qRT-PCR expression data 12 
by using ExoPipe (see methods). The raw data were normalized according to the 13 
Global Mean Method (56). The Global Mean method was effective in reducing 14 
technical variability as it is shown in Figure 17. After filtering and imputation we 15 
obtained a total number of 61 miRNA to be considered for further analysis (data 16 
not shown).  17 







Figure 17. Cumulative distribution of miRNA coefficient of variation (CV) values. The 3 
cumulative distribution of miRNA CV values in the LS-G6pc-/- mice sample set when no 4 
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4.11. LS-G6pc-/- mice with HCA express deregulated miRNA 1 
We compared LS-G6pc-/- mice versus WT mice and LS-G6pc-/- with HCA mice 2 
versus LS-G6pc-/- mice without HCA, to identify significantly deregulated 3 
miRNA.   4 
 5 
Bioinformatic analysis of exo-miR identified 9 and 5 significantly deregulated 6 
miRNA in LS-G6pc-/- mice comparing with WT mice and in LS-G6pc-/- mice with 7 
adenoma compared with LS-G6pc-/- without adenoma, respectively (Table 9 and 8 













Table 9. Differentially expressed miRNA in LS-G6pc-/- mice. The arrow’s direction 22 
indicates the up- or down-regulation.  23 
 24 
miRNA LS-G6pc-/- VS WT HCA VS no HCA 
139-3p ­  
190b ­  
380-5p ­  
381-5p ­  
434-5p ­  
24 ¯  
29a ¯  
145  ¯  
342  ¯  
409 ­  
486  ¯  
744 ¯  
192  ­ 
685  ¯ 
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We plotted the expression of  all miRNA for each mouse to visualize the  1 
deregulation of these miRNA in LS-G6pc-/- mice. Here, we selected miR-744 2 






Figure 18. Scatter plot for miR-744 and miR-29a in all 63 mice. 9 
Panels A and B show the expression of miRNA 744 and 29a. Data are relative to 45 LS-G6pc-10 
/- and 18 WT mice. The first 45 samples refer to LS-G6pc-/-. Both of these miRNA were found 11 




bHCA are at a greater risk of malignant transformation into HCC. In the attempt 1 
to differentiate low-risk adenomas from high-risk adenomas, we subclassified 2 
mice in groups according with the different types of HCA they developed. We 3 
found two miRNA (miR-27a, miR-335) that seemed to be differentially expressed 4 
in mice with bHCA and/or HCC. Nevertheless, further analysis are required, since 5 
these mice show frequently adenomatosis, with the development of different types 6 
of adenomas in the same mouse, making very difficult to differentiate miRNA 7 
derived from one kind of tumor from another.  8 
The 16 deregulated miRNA found in LS-G6pc-/- mice are linked to multiple 9 
functions and pathways. The majority of them are reported to be involved in 10 
cancer-related processes (60-64). Interestingly, some of these miRNA (miR-29a, 11 
miR-145, miR-342, miR-744, miR-335) are involved in pathways that are of 12 
potential relevance for liver disease and HCA and HCC pathophysiology. These 13 
exo-miR will be validated by qRT-PCR. Analysis of these data is still ongoing 14 













DISCUSSION  1 
Several animal models of liver disease have been developed and extensively 2 
utilized in many preclinical medical research studies to investigate disease onset 3 
and progression (65-69).  4 
Development of HCA in LS-G6pc-/- mice is the consequence of a single gene 5 
mutation that inhibits the G6Pase function and leads to liver degeneration and 6 
tumorigenesis. Thus, LS-G6pc-/- mice are of major interest because they mimic 7 
spontaneous HCA formation with aging and its evolution into HCC as in GSD1a 8 
patients.  9 
To date there has been a lack of appropriate in vivo detection system that allows 10 
a continuous monitoring of tumor onset and progression.  HCC high-risk patients 11 
are monitored through imaging surveillance, and focal nodules characterization is 12 
performed with multiphase contrast material-enhanced computed tomography 13 
and/or MRI. Because of variability in lesion interpretation, the Liver Imaging-14 
Reporting and Data System (LI-RADS) was created with the aims of improving 15 
HCC diagnosis and therapeutic management (70).  16 
Hepatobiliary contrast agents have significantly increased diagnostic accuracy in 17 
the detection and characterization of focal liver lesions and its role was recently 18 
recognized also in the latest version of  CT/MRI LI-RADS criteria (v2017) which 19 
considers HBP as an ancillary feature in lesion characterization i.e. HPB phase 20 
hypointensity favoring malignancy in general and  HBP isointensity favoring 21 
benignity (71). 22 
We set up a protocol to assess the detection level and quantify the longitudinal 23 
evolution of liver lesions in LS-G6pc-/- mice using non-contrast T1-WI/T2-WI 24 
and non-dynamic post-contrast hepatobiliary imaging. We based our differential 25 
diagnosis on features considered ancillary by LI-RADS, especially mild to 26 
moderate T2 hyperintensity. The hepato-specific contrastographic phase allows to 27 
differentiate lesions on the basis of hepatocyte function and contrast uptake. We 28 
used Gd-BOPTA that, in the clinical practice, has high relaxivity values (72) but 29 
only 5% of biliary excretion at 1-2 hours after administration. The use of Gd-30 
BOPTA in mice has two main advantages: hepatobiliary phase is already present 31 
about 10 minutes after contrast administration, and hepatobiliary excretion is 32 
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about 50%, because of a different pharmacokinetic profile, as previously 1 
demonstrated (73) 2 
The detection of small HCC is challenging also in the clinical practice. In fact, the 3 
detection rate of human HCC <1 cm in diameter is only 34% (74). Our protocol 4 
allows the visualization and monitoring of small HCC/HCA nodules with a 5 
diameter of 1 mm and represents an important improvement in imaging technique 6 
of murine liver nodules compared with other study reporting some difficulty in 7 
detecting lesions ≤ 2 mm (75).   8 
The major advantage of our protocol is the possibility to detect high-risk adenoma 9 
subtypes. In fact, by combining information of all sequences, and especially 10 
contrast enhanced T1-WI, we were able not only to detect very small size lesions 11 
but also to characterize and differentiate them into different histological HCA 12 
subtypes.  13 
UHCA remains the less characterized adenoma subtype, with no specific 14 
genetic/pathologic abnormalities and no specific MRI pattern. In fact, UHCA 15 
showed all 4 different contrast enhancement patterns and the majority were 16 
isointense on T2-WI. During the follow up study we noticed that UHCA showing 17 
an MRI pattern typical of IHCA have a slow growth rate while UHCA with 18 
evolving features and with an MRI pattern typical of bHCA displayed a high 19 
growth rate. Bioulac-Sage and collaborators3 reported that b-catenin activation 20 
was not detected in all nodules of the same patient with adenomatosis and 21 
suggested that b-catenin mutation could occur later during adenoma 22 
carcinogenesis, promoting malignant transformation. Further studies will be 23 
required to better understand oncogenesis and identify possible differences in 24 
clinical features and pathologic and radiologic characteristics of this 25 
heterogeneous HCA subtype. In this respect, due to the rarity of UHCA, 26 
preclinical models can be useful tools to improve our knowledge in this field. 27 
Nevertheless, our results suggest that some UHCA could be considered as the 28 
precursors of bHCA at an early stage of carcinogenesis. 29 
We show here that bHCA display MRI features distinguishable from those 30 
exhibited by IHCA or UHCA, indicating that our protocol is a reliable method to 31 
identify high risk HCA. This is an important achievement because GSD1a patients 32 
often develop multiple adenomas that may originate from independent clones and 33 
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therefore have different molecular subtypes. Because HCA is a rare disease, the 1 
information in the literature to help guide treatment is low. The possibility of 2 
characterizing the different HCA subtypes in patients with multiple adenomas is 3 
important for planning surveillance and treatment. 4 
In conclusion, this is the first study in literature reporting the possibility to 5 
differentiate the various subtypes of hepatic adenoma using MRI imaging. In this 6 
respect, the establishment of an optimized MRI protocol to detect and analyze 7 
liver lesions in our mouse model for GSD1a opens the possibility to apply such a 8 
protocol to patients for non invasive diagnostic purposes. A very recent study 9 
utilized a similar MRI protocol to screen for HCC in patients with cirrhosis or 10 
chronic hepatitis B. Reported results indicate that MRI characteristics similar to 11 
ours are suggestive of malignant transformation (76).  12 
Our objective was also to define a signature correlated with disease progression 13 
and tumor onset. Mass spectrometry is a very important tool for investigating 14 
protein expression and protein characteristics on a large scale (77). LC-MS-based 15 
proteomics has become a widely used technique to analyze biological samples 16 
(78,79), and its successful application has been reported in the literature for 17 
several diseases (80).  18 
We found 1243 proteins that were modulated in livers derived from diseased 19 
animals in comparison with WT mice. In LS-G6pc-/- mice proteins involved in 20 
several metabolic processes including lactic acid production, glycolysis, pyruvate 21 
metabolism fatty acid and cholesterol biosynthesis, and response to hypoxia as 22 
well as proteins involved in inflammatory response, mitochondrial activity and 23 
immune response were modulated. The expression of many of these proteins 24 
increased or decreased over time, indicating an association between their altered 25 
expression and liver disease.    26 
The liver is involved in metabolism and storage of nutrients in the form of 27 
glycogen and lipids and supplies energy-producing substrates to the peripheral 28 
tissues. These processes require a considerable amount of oxygen, which causes 29 
a steep oxygen gradient throughout the hepatic lobules (81). During some 30 
pathological conditions the hepatic metabolic balance can be altered resulting in 31 
disruption of hepatic oxygen homeostasis and severe liver hypoxia (81).  32 
Hypoxia is a condition of low oxygen tension occurring in poorly or irregularly 33 
vascularized tissue areas, which has profound effects on cell growth, metabolism, 34 
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genotype selection, susceptibility to apoptosis, epithelial-to-mesenchymal 1 
transition and angiogenesis (82,83).   Hypoxia is a hallmark of several human 2 
cancers and contributes to resistance to radio- and chemotherapy, tumor 3 
progression, metastatization, and poor prognosis (84-86). Although the link 4 
between hypoxia and GSD1a has not been reported, hypoxia has been implicated 5 
in the pathogenesis of a broad range of hepatic diseases including viral hepatitis, 6 
liver injury, liver fibrosis and hepatocellular carcinoma (87).  We report proteomic 7 
data that suggest the presence of a hypoxic state in the livers from LS-G6pc-/- 8 
mice, irrespectively of mouse age. While overexpression of some of these proteins 9 
(ALDOA ALDOB PKLR GPI ENO1 LDHA PGK1 PFKL) is consistent with 10 
enhanced hepatic glycolytic pathway, overexpression of others (FBP1 UGP2 TPI1 11 
PCK1) is consistent with enhanced gluconeogenesis, suggesting that both 12 
metabolic pathways are activated in LS-G6pc-/- livers. Genes belonging to the 13 
gluconeogenesis and glycolysis pathways, pH regulation, and angiogenesis are 14 
induced under hypoxic conditions. This group of genes defines a constant feature 15 
of the hypoxic status of cells of different types, origin and functional state (82). 16 
Moreover, among the proteins modulated in the livers of LS-G6pc-/-, whose 17 
coding genes were part of the HALLMARK_HYPOXIA gene set (Figure 12), we 18 
observed upregulation of PDK1, a kinase that has an important role in protecting 19 
cells against apoptosis in response to hypoxia and oxidative stress, S100A4, a 20 
protein involved in the regulation of a number of cellular processes such as cell 21 
cycle progression and differentiation and whose altered expression has been 22 
implicated in tumor metastasis; LDHA which supports ATP request by glycolysis 23 
and is compatible with lactic acidemia frequently affecting GSD-1a patients. 24 
Interestingly, the production of lactate is a tumor promoting condition that support 25 
M2 polarization of macrophages (88,89) and protects tumor cells from glucose 26 
deprivation.  27 
Thus, our findings suggest that hypoxia is a pervasive condition of LS-G6pc-/- 28 
mouse livers and highlight the possible role of hypoxia in GSD-1a, capable of 29 
affecting hepatocyte biological processes and liver microenvironment with a 30 
potential role in the progression of the disease.   31 
LS-G6pc-/- mice also display upregulation of several enzymes involved in de novo 32 
biosynthesis of fatty acids (as well as their elongation and desaturation) (Table 7). 33 
This is consistent with steatosis in LS-G6pc-/- mice livers. However, livers of older 34 
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LS-G6pc-/- mice also show up-regulation of CPT1A, the enzyme that, regulating 1 
the entry of fatty acids into the mitochondria, catalyzes the rate-limiting step of 2 
mitochondrial fatty acid β-oxidation. The increase of β-oxidation could be an 3 
attempt of adaptive response to reduce the lipid overload and lipotoxicity, but the 4 
dysfunction in OXPHOS due to the downregulation of several proteins of the 5 
respiratory chain complexes and of ATP synthase, which we observed in these 6 
mice, makes this metabolism insufficient in normalizing lipid levels. In addition, 7 
the dysfunction in OXPHOS results in increased levels of mitochondrial NADH 8 
(from glycolysis and β-oxidation) that, by inducing the export of citrate and malate 9 
into the cytosol because of Krebs cycle inhibition, further promotes lipid 10 
biosynthesis as well as gluconeogenesis and cholesterol synthesis, as indicated by 11 
the upregulation by several enzymes involved in these pathways. Thus, our data 12 
from proteomic analysis sustain a metabolic reprogramming of glucose-6P 13 
leading to the accumulation of lactate, fatty acids and cholesterol, all implicated 14 
in liver damage and crucial for liver disease progression.  15 
Interestingly, older LS-G6pc-/- mice also show upregulation of aconitase (ACO1), 16 
Aspartate aminotransferase (GOT2), alanine aminotransferase 1 (GPT), amino 17 
transferase (AT) and isocitrate dehydrogenase (IDH1), all involved in 2-18 
oxocarboxilic acid metabolism, a process essential in hypoxic conditions and in 19 
cancer cells with mitochondrial defects (90).  A summary of the metabolic 20 
pathways altered in the affected livers of aged LS-G6pc-/- mice is shown in Figure 21 







Figure 19. Diagram of the metabolism deregulation in the old mice livers. The 4 
abbreviations used for the proteins are the same as in Table 7. 5 
 6 
Non alcoholic fatty liver disease, NAFLD, is a liver disorder characterized by the 7 
presence of steatosis in more than 5% of hepatocytes and is not correlated with 8 
alcohol consumption (91). NAFLD has frequently been associated with obesity, 9 
type 2 diabetes mellitus, hyperlipidemia, and insulin resistance and, for this 10 
reason; it is considered the hepatic manifestation of the metabolic syndrome (92). 11 
Moreover, patients with NAFLD are at an increased risk of developing HCC (93). 12 
The molecular mechanisms that underlie the pathophysiological changes of 13 
hepatic lipid metabolism in NAFLD include inflammation, drug metabolism, 14 
synthesis of endogenous fatty acids, lipotoxicity, and PPARs activation (94).   15 
Moreover, the Cytochrome P450  epoxygenase pathway has been indicated as 16 
another important regulator of the hepatic inflammatory response in mice with 17 
fatty liver disease (95). During NAFLD, several metabolic adaptations are set up 18 
by mitochondria in order to restrain fat accumulation. Some of these mechanisms, 19 
such as mitochondrial fatty acid oxidation, may aggravate oxidative stress and 20 
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impair energy output resulting in severe mitochondrial dysfunction (96). Finally, 1 
macrophage polarization and inflammatory signals appear to be central for the 2 
pathogenesis and progression of NAFLD (97).  With this analysis, we have 3 
identified a set of significantly altered proteins in LS-G6pc-/-, respect to wild type 4 
mice, that are involved in NAFLD, i.e. innate immune response, inflammatory 5 
response and mitochondrion dysfunction, suggesting that LS-G6pc-/-  mice are 6 
affected by NAFLD.  7 
We performed a proteomic analysis of liver samples from LS-G6pc-/- mice that 8 
had developed HCA in comparison with liver samples from mice that had not. 9 
Among proteins identified in LS-G6pc-/- mice developing adenomas, we identified 10 
two important complement components, the component C3, which modulates 11 
inflammation, and the component C5, which is part of the innate immune system 12 
and plays an important role in inflammation, host homeostasis and host defense 13 
against pathogens. These proteins play a key role in the regulation of 14 
inflammatory cells accumulation in the tissues. In particular, C5 seems to be 15 
important for the recruitment of myeloid-derived suppressor cells, which promote 16 
immunosuppression that is linked to tumor growth (98,99).  Macrophages 17 
represent a major component of the leukocyte infiltrate at sites of inflammation 18 
infection, tissue damage and tumor growth and can differentiate into a spectrum 19 
of phenotypic states in response to diverse environmental signals (98). 20 
The classically activated (type 1 proinflammatory or M1) macrophages display 21 
proinflammatory and effector properties and mediate antimicrobial defense, tissue 22 
destruction, and antitumor resistance (98,99). Conversely, the alternatively 23 
activated (type 2 anti-inflammatory or M2) macrophages exhibit tissue 24 
remodeling and repair functions, promote wound healing, angiogenesis, and 25 
resistance to parasites (98,99), they accumulate in most human cancers (tumor 26 
associated macrophages, TAMs), supporting tumor progression, metastatic 27 
dissemination and cancer immune evasion (100,101).  28 
Macrophages are a key component of the homeostatic functions of the liver. In 29 
response to damaged liver tissue, macrophages undergo polarization into M1 or 30 
M2 activation states, mirroring in vitro polarized mononuclear phagocytes (98). 31 
Interestingly, we found upregulation of several markers of macrophage 32 
polarization towards the M2 phenotype in the liver of mice with HCA, including 33 
the mannose receptor C-type 1, arginase 1, the scavenger receptor CD163, and 34 
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STAT6, suggesting the accumulation in the liver of M2-polarized macrophages.  1 
We also found that the expression of these markers in the livers of LS-G6pc-/- 2 
mice is modulated in an age dependent manner (data not shown). Therefore, M2 3 
type macrophages are present in these livers and their accumulation may correlate 4 
with tumor onset and progression. Inflamed livers express high levels of lectin 5 
receptors, such as CLEC4D and CLEC4E, which respond to the 6 
microenvironment by promoting the innate response (52). In this respect, mannose 7 
binding lectins A and C are upregulated in LS-G6pc-/- mice livers.  8 
All these results are compatible with the hypoxic pathologic environment of LS-9 
G6pc-/- mice livers, The role of hypoxia in macrophage polarization is in fact 10 
beginning to emerge 102,103) and hypoxia is known to upregulate M2 markers 11 
both in rodent and in human macrophages (58,59).  In addition, lactic acid 12 
produced in LS-G6pc-/- mice livers as a by-product of aerobic or anaerobic 13 
glycolysis, typically indicative of hypoxia, may be important for inducing the 14 
accumulation of M2-polarized macrophages. Colegio  and coworkers (104)  15 
demonstrated that lactic acid, produced by tumor cells, has a critical function in 16 
inducing M2-like polarization of tumor-associated macrophages and macrophage 17 
expression of arginase 1, which has an important role in tumor growth. Cells of 18 
the monocyte-macrophage lineage are crucial drivers of tumor-promoting 19 
inflammation and play a key role in cancer, contributing to tumor progression 20 
(105). Therefore, the hypoxic state of LS-G6pc-/- livers combined with promotion 21 
of macrophage polarization towards M2 phenotype may represent the 22 
environmental condition for hepatic tumor development and progression and can 23 
provide tools to tailor cytoreductive therapies and immunotherapy. 24 
These results identify a metabolic reprogramming of glucose-6-P and a pathologic 25 
environment in the liver of GSD-1a mice compatible with tumor development and 26 
progression.  27 
We also evaluated whether miRNA may represent potential biomarkers of tumor 28 
onset and progression in GSD1a. We studied exosomes derived from peripheral 29 
blood of LS-G6pc-/- mice, comparing the expression profile of exo-miR in mice 30 
with different clinical characteristics to determine whether miRNA differential 31 
expression can be indicative of tumor onset and progression. An advantage of 32 
using the LS-G6pc-/- mice was the possibility to perform a preliminary analysis in 33 
a homogenous model, with a common genetic background and uniform disease 34 
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progression. This initial approach allowed us to identify and select a restricted 1 
number of miRNA that are dysregulated in GSD1a. These miRNA were subjected 2 
to a bioinformatic analysis to gather information on their possible role in GSD1a 3 
pathophysiology and HCA development.  4 
The miRNA we found to be dysregulated in GSD1a mice with tumor were 5 
potentially relevant for the disease pathophysiology according to the 6 
bioinformatic and literature analysis (106-110). Furthermore they were 7 
measurable in samples, like plasma, that can be readily available in patients and 8 
require minimally invasive procedures. Among the dysregulated miRNA, miR-9 
29a, miR-145, miR-342, miR-744 and miR-335were particularly attractive, 10 
because they had already been proposed as a biomarker for liver diseases and liver 11 
tumorigenesis (60-64), and may allow for the identification of a specific 12 
“signature” of HCA onset, and of disease progression, outcome, or response to 13 
therapies. In summary, our results demonstrate that the blood of LS-G6pc-/- mice 14 
contains tumor-specific exosomes and that exo-miR can efficiently be isolated 15 
from plasma specimens and may be used as prognostic/diagnostic biomarkers. 16 
The exosomal miRNA signatures we have derived represent the liver specific 17 
contribution to the exosomal miRNA profile of HCA development. Moreover, 18 
further analysis may allow a correlation between miRNA profile and bHCA, of 19 
particular prognostic relevance for the development of HCC.  20 
The mouse model utilized has allowed the clear definition of the liver contribution 21 
to the exosomal miRNA profile because it is the only organ affected by the 22 
deletion of the G6pPase-α. Our model has been an essential tool to study the role 23 
of exosomal miRNA in the onset of HCA and HCC. miRNA that we have 24 
identified can be used as biomarkers for the onset and the malignant 25 
transformation of hepatic tumors. Our results could be useful for therapeutic 26 
strategies against liver degeneration that leads to HCA and HCC, and for 27 





The ongoing and future studies are focused on: 1 
Correlate miRNA expression with HCA progression over time. 2 
We will evaluate exo-miR profile during the evolution of liver lesions detected 3 
and quantified with the MRI protocol we developed.  4 
Mice will be periodically analyzed for the presence of HCA, starting at the age of 5 
10-11 months, by MRI. 6 
This analysis will determine the presence or absence of HCA, their subdivision in 7 
IHCA, bHCA and UHCA and/or HCC to be correlated with the exo-miR profile 8 
that will be determined from plasma samples collected at each MRI analysis. Mice 9 
will be sacrificed after the last MRI session at the age of 16-17 month, and HCA 10 
classification will be confirmed by immunohistochemistry.  11 
 12 
Correlate miRNA expression of LS mice with miRNA expression in GSD1a 13 
patients. 14 
We have established a collaboration with Dr. M. Di Rocco (Unit of Rare Diseases, 15 
Department of Pediatrics, G. Gaslini Institute, Genova), Dr. Daniela Melis 16 
(Department of Translational Medical Sciences, Section of Pediatrics, Federico II 17 
University, Napoli), Prof. Enrica Riva (Department of Pediatrics, San Paolo 18 
Hospital, University of Milano), Dr. Annalisa Sechi (Regional Coordinator Center 19 
for Rare Diseases, University Hospital “Santa Maria della Misericordia, Udine), 20 
and Dr. David Weinstein (Connecticut Children’s Hospital, Farmington, Ct, USA) 21 
who have recruited the GSD1a patients to be included in this project.  22 
Patients between one and 45 years of age, undergoing periodic evaluation, have 23 
been included in the study. Age matched healthy donors have been enrolled as 24 
control. Presently, we have already extracted exo-MiR from the plasma of 80 25 
patients. This cohort represents a substantial number of cases sufficient for 26 
statistical evaluation. The low number of patients at risk of HCC may be an 27 
obstacle for statistical evaluation. Should this be the case, we will rely on the 28 
mouse model data to map the exosomal miRNA profile for a correlative support 29 
of the findings. miRNA bioinformatic analysis is already ongoing, and as a result 30 
of this analysis, we will identify the human miRNA signatures characterizing the 31 
presence of adenomas in GSD1a patients. These miRNA can allow an early 32 
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prediction of the adenoma development, and could be used to develop protocols 1 
for the therapeutic targeting of miRNA. 2 
In fact, pathological expression of miRNA can be controlled by a new generation 3 
of drugs that, by antagonizing or restoring miRNA function in the target cell, 4 
attempt to normalize the homeostasis of the tissue. miRNA-targeting therapies are 5 
an area of strong interest and many such compounds are in preclinical and clinical 6 
development for a variety of diseases. miRNA mimic molecules and antisense 7 
inhibitors are in phase I or preclinical studies for treatment of cancer, including 8 
hepatocellular carcinoma and glioblastoma, and other human diseases such as 9 
heart failure and insulin resistance (111). 10 
We hope that our findings may be translated to the human setting and therefore 11 
may constitute the basis for the development of an appropriate screening and 12 
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